Allosteric regulation and substrate activation in cytosolic nucleotidase II from Legionella pneumophila

Bharath Srinivasan1,*, Farhad Forouhar2, Arpit Shukla1, Chethana Sampangi1, Sonia Kulkarni1, Mariam Abashidze2, Jayaraman Seetharaman2, Scott Lew2, Lei Mao3,4, Thomas B. Acton3,4, Rong Xiao3,4, John K. Everett3,4, Gaetano T. Montelione3,4, Liang Tong2 and Hemalatha Balaram1

1 Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, Karnataka, India
2 Department of Biological Sciences, Northeast Structural Genomics Consortium, Columbia University, New York, NY, USA
3 Department of Molecular Biology and Biochemistry, Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ, USA
4 Department of Biochemistry, Robert Wood Johnson Medical School, Northeast Structural Genomics Consortium, Piscataway, NJ, USA

Keywords
5′-nucleotidase; allostery; GMP-complexed LpcN-II structure; heterotropic activation; substrate activation

Correspondence
L. Tong, Department of Biological Sciences, Northeast Structural Genomics Consortium, Columbia University, New York, NY 10027, USA
Fax: +1 212 865 8246
Tel: +1 212 854 5203 and;
H. Balaram, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560 064, Karnataka, India
Fax: +91 80 2208 2756
Tel: +91 80 2208 2812
E-mails: ltong@columbia.edu; hb@jncasr.ac.in

*Present address:
Center for the Study of Systems Biology, Atlanta, GA, USA

B. Srinivasan and F. Forouhar contributed equally to this work.

(Received 2 October 2013, revised 24 December 2013, accepted 21 January 2014)

doi:10.1111/febs.12727

Abbreviations
cN-II, cytosolic nucleotidase II; GMP-PNP, Guanosine 5′-[β,γ-imido]triphosphate; LpcN-II, Legionella pneumophila cytosolic nucleotidase II; pNPP, p-nitrophenyl phosphate.

Cytosolic nucleotidase II (cN-II) from Legionella pneumophila (Lp) catalyzes the hydrolysis of GMP and dGMP displaying sigmoidal curves, whereas catalysis of IMP hydrolysis displayed a biphasic curve in the initial rate versus substrate concentration plots. Allosteric modulators of mammalian cN-II did not activate LpcN-II although GTP, GDP and the substrate GMP were specific activators. Crystal structures of the tetrameric LpcN-II revealed an activator-binding site at the dimer interface. A double mutation in this allosteric-binding site abolished activation, confirming the structural observations. The substrate GMP acting as an activator, partitioning between the allosteric and active site, is the basis for the sigmoidicity of the initial velocity versus GMP concentration plot. The LpcN-II tetramer showed differences in subunit organization upon activator binding that are absent in the activator-bound human cN-II structure. This is the first observation of a structural change induced by activator binding in cN-II that may be the molecular mechanism for enzyme activation.

Database
The coordinates and structure factors reported in this paper have been submitted to the Protein Data Bank under the accession numbers 2BDE and 4G63. The accession number of GMP complexed LpcN-II is 4OHF.

Structured digital abstract
• LpcN-II and LpcN-II bind by molecular sieving (View interaction)
• LpcN-II and LpcN-II bind by x-ray crystallography (View interaction)

[Structured digital abstract was added on 5 March 2014 after original online publication]
Introduction

5′-Nucleotidases (EC 3.1.3.5) are a large family of enzymes that catalyze the dephosphorylation of ribo- and deoxyribonucleoside monophosphates to their corresponding nucleosides [1]. Based on their cellular localization, 5′-nucleotidases are broadly classified as membrane-bound and soluble forms, with the latter further subdivided into categories based on their substrate specificity. Cytosolic nucleotidase I (cN-I) shows specificity for AMP and pyrimidine nucleoside monophosphates, cytosolic nucleotidase-II (cN-II) shows specificity for IMP and GMP, cytosolic nucleotidase III (cN-III) shows specificity for pyrimidine nucleoside monophosphates and IMP-specific 5′-nucleotidase, a new class of 5′-nucleotidases, shows specificity for IMP [2,3]. All soluble 5′-nucleotidases are members of the haloacid dehalogenase superfamily of enzymes [4,5].

cN-II class nucleotidases play critical roles in maintaining the flux through the purine nucleotide cycle and the oxypurine cycle, pathways which generate critical metabolites like fumarate, ammonia, phosphoribosyl pyrophosphate and ribose-1-phosphate [6]. Given the critical role of cN-IIs, this enzyme from mammalian sources shows multiple levels of regulation. Mammalian cN-IIs display sigmoidal velocity versus substrate concentration plots for the hydrolysis of their substrate IMP, inhibition by inorganic phosphate [7], and heterotropic activation by ATP [8], 2,3-bisphosphoglyceric acid [9], polyphosphates [10] and diadenosine polyphosphates [11]. Although reports unambiguously establishing the mechanism of activation of mammalian cN-II are lacking, it has been speculated that binding of the activator facilitates the formation of higher order enzyme oligomers [12]. The structures of the apo and various complexed forms of the human cN-II identify the effector-molecule-binding site, although no conformational change is seen upon activator binding [13,14]. It was proposed that the effector-induced disorder-to-order transition, generating rearrangements within the catalytic site and the subsequent coordination of the catalytically essential magnesium, is the probable mechanism of activation. However, it should be noted that the human cN-II used for crystallographic studies corresponds to 1–536 of 561 residues [13,14]. It has been shown previously that truncation of 13 residues from the C-terminus in human cN-II leads to a 33-fold reduction in Vmax and a 2.5-fold increase in Km for the substrate IMP, along with a 55-fold reduction in the activation of IMP hydrolysis by ATP [12].

Here, we report the detailed biochemical, kinetic and structural characterizations of recombinant L. pneumophila cN-II (LpcN-II), the first prokaryotic cN-II to have been studied. LpcN-II prefers GMP over IMP as its substrate, and has an obligate requirement for the divalent cation Mg2+. GTP was found to be a novel activator of the enzyme, modulating the Km without significantly affecting the Vmax for the substrate GMP. The enzyme displayed a unique feature of substrate activation by GMP. To understand the mechanism of activation, we report the PO4- and GMP-complexed crystal structures of the enzyme. Although crystallization was in the presence of GMP-PNP, electron density was evident only for the GMP moiety. GMP binds at the dimer interface and this binding site has been validated by mutation of the contacting residues R86 and Y421. A tilt of one subunit with respect to another was observed when the PO4- and GMP-complexed structures were superposed, a feature unlike the human cN-II structures which do not exhibit altered organization upon ligand binding. Possible peptide connectivities between the active and effector sites that may serve as structural conduits are discussed.

Legionella pneumophila is the causative agent of Legionnaires’ disease. Understanding the metabolism of the pathogen is a prerequisite for devising effective intervention strategies. cN-II activity is indispensable for the survival of astrocytoma cells [15]. Being a pivotal enzyme in nucleotide metabolism, differences in the structure and regulation of human and L. pneumophila cN-II could be exploited to devise appropriate intervention strategies for Legionnaires’ disease.

Results

Biochemical characterization, substrate specificity and kinetic parameters of LpcN-II

Purified recombinant hexa-histidine-tagged full-length LpcN-II (Fig. S1A–C), upon examination using size-exclusion chromatography, was a tetramer at 20 µm protein concentration (Fig. S1D). LpcN-II readily catalyzed the breakdown of selected nucleoside monophosphates (Table S1) and the preferred effector for the reaction was Mg2+ followed by Mn2+. GMP was found to be the most preferred substrate, followed by dGMP and IMP; activity on AMP, XMP, CMP and UMP was poor. The initial velocity versus substrate concentration plots for GMP and dGMP were sigmoidal, whereas IMP curves were biphasic (Fig. 1A–C). Summarized in Table 1 are the
The kinetic parameters of LpcN-II for various substrates and cofactors. The $K_m$ values for all the substrates are in the mM range, similar to other cN-Is and cN-IIIs that have high $K_m$ values (1–15 mM) for AMP/IMP [1]. The enzyme displayed highest catalytic efficiency for GMP with a $k_{cat}/K_m$ value of 1.7 mM$^{-1}$s$^{-1}$. The sigmoidicity of the initial velocity plot is evident in the high values of Hill coefficient ($n_H$). When compared with mammalian cN-Is, LpcN-II exhibits lower affinity for IMP (Table S2). LpcN-II also hydrolyzed p-nitrophenyl phosphate (pNPP) at a much lower catalytic efficiency, with hyperbolic velocity versus substrate concentration plots. It should be noted that pNPP is not a physiologically relevant substrate. However, this activity of LpcN-II was amenable to continuous monitoring of product formation and hence was exploited to understand the kinetic behavior of LpcN-II activation.

**Fig. 1.** Substrate titration plots of LpcN-II for (A) GMP, (B) dGMP and (C) IMP. Plots in (A) and (B) show sigmoidal kinetics, whereas (C) shows biphasic kinetics. The insets in (A) and (B) show the Hill plot of log($v/(V_{max} - v)$) versus log (substrate) with the slope value of the line indicated. The inset in (C) shows the Hill plot of log($v/(V_{max} - v)$) versus log (IMP) indicative of negative homotropic cooperativity. The slope indicated is for the mid-region (highlighted by arrow) of the plot. Data were fitted to the Hill equation (Equation 1 in the Supporting information) using GRAPHPAD PRISM software, v. 4.0 (GraphPad Software, Inc., San Diego, CA, USA). $v$ refers to the initial velocity. SA stands for specific activity.
Table 1. Summary of kinetic parameters of LpcN-II for various substrates and cofactors.

<table>
<thead>
<tr>
<th>Substrate number</th>
<th>Substrate/ pseudo substrate</th>
<th>$S_{0.5}$ or $K_m$ (mM)</th>
<th>$V_{max}$ (μmol·min$^{-1}$·mg$^{-1}$)</th>
<th>$k_{cat}$ (s$^{-1}$)</th>
<th>$k_{cat}/K_m$ or $k_{cat}/S_{0.5}$ (μmol·min$^{-1}$·s$^{-1}$)</th>
<th>$n_H$</th>
<th>Type of kinetic profile</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>GMP$^b$</td>
<td>7.2 ± 0.3</td>
<td>13.2 ± 0.4</td>
<td>12.4</td>
<td>1.7</td>
<td>2.1</td>
<td>Sigmoidal</td>
</tr>
<tr>
<td>2</td>
<td>dGMP$^b$</td>
<td>142 ± 17</td>
<td>23 ± 2</td>
<td>20.7</td>
<td>0.15</td>
<td>1.7</td>
<td>Sigmoidal</td>
</tr>
<tr>
<td>3</td>
<td>IMP$^{ik,i}$</td>
<td>18 ± 9$^c$</td>
<td>0.4 ± 0.1$^d$</td>
<td>0.3</td>
<td>0.02</td>
<td>–</td>
<td>Biphasic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>118 ± 10$^g$</td>
<td>1.3 ± 0.2$^g$</td>
<td>1.2</td>
<td>0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>pNPP$^b$</td>
<td>5.1 ± 0.9</td>
<td>1.0 ± 0.1$^h$</td>
<td>$1.0 \times 10^{-3}$</td>
<td>$0.1 \times 10^{-3}$</td>
<td>1</td>
<td>Hyperbolic</td>
</tr>
<tr>
<td>5</td>
<td>MgCl$_2$</td>
<td>1.1 ± 0.1</td>
<td>0.9 ± 0.0$^h$</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6</td>
<td>MnCl$_2$</td>
<td>0.5 ± 0.2</td>
<td>0.3 ± 0.0$^h$</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

$^a$Either $S_{0.5}$ or $K_m$ is used depending on the kinetic profile. $^b$Metal ion used was 30 mM MgCl$_2$. $^c$Lower and higher $K_m$ values for IMP from $v$ versus (S) biphasic curves. $^d$Lower and higher $V_{max}$ values for IMP from $v$ versus (S) biphasic curves. $^e$nmol·min$^{-1}$·mg$^{-1}$. $^f$Substrate was 15 mM pNPP. $^g$The parameters were derived from extrapolation of intercepts from Eadie–Hofstee plots.

Heterotropic allosteric activation of LpcN-II by GTP, dGTP and GDP

A list of compounds screened for their effect on the pNPP-hydrolyzing activity of LpcN-II is provided in Table S3. Although activators of the mammalian enzyme had no effect on the prokaryotic enzyme, GTP, dGTP and GDP showed activation of LpcN-II activity. The dissociation constant ($K_D$) of GTP was 4.2 ± 0.4 mM under catalytic conditions and 4.1 ± 0.7 mM under equilibrium conditions (Fig. S2A, B). The absence of activation by ATP and ITP with potent activation by GTP, dGTP and GDP indicates that the C2 amino group on the purine ring is indispensable for the activation of LpcN-II. It should also be noted that GTP is not hydrolyzed by the enzyme, as evident from Chen’s assay and ion-pair reverse phase HPLC (IP-RP-HPLC).

K-type activation of GMP hydrolysis by GTP

Activation of GMP hydrolysis by GTP was checked by estimating the liberated phosphate. With increasing GTP concentrations, the sigmoidicity of the velocity versus [GMP] plot reduced (Hill coefficient reduced from 2.1 in the absence of GTP to 1.2 at 5 mM GTP; Fig. 2A and Table S4). This is also evident in the double reciprocal plot of $1/v$ versus $1/[	ext{GMP}]$ where the nonlinearity was abolished as the GTP concentration increased (Fig. 2A, inset). Further, in the $v$ versus (S) plot for GMP hydrolysis, the maximum difference of approximately eightfold in product formation between the unactivated and activated LpcN-II was seen at 1.5 mM substrate and 1 mM GTP concentrations. This observation was confirmed by ion-pair RP-HPLC, wherein under similar conditions, a ninefold increase in guanosine formation was seen (Fig. 2B). Under similar assay conditions, ATP did not show an increase in the rate of GMP hydrolysis.

Allosteric systems that demonstrate altered substrate affinity upon effector binding are referred to as ‘K-type’ systems [16]. Activation of GMP hydrolysis by GTP is ‘K-type’ because the activator reduces the $K_m$ without altering the $V_{max}$. The $K_m$ for GMP in the absence of added GTP was 7.2 ± 0.3 mM, but this was reduced to 5.1 ± 0.3 mM in the presence of 5 mM GTP. $Q_{ax}$, expressed as $K_{ia}/K_{ia,x}$, where $K_{ia}$ is the $K_D$ of the enzyme-substrate complex and $K_{ia,x}$ is the $K_D$ of the enzyme-substrate complex in the presence of the activator, is 1.41, which shows that GTP causes an increase in the enzyme’s affinity for the substrate.

V-type activation of pNPP hydrolysis by GTP

The time course of pNPP hydrolysis approached saturation within 200 s of the initiation of the reaction in the presence of GTP, whereas ATP did not activate the enzyme (Fig. 2C and inset). The $V_{max}$ for pNPP hydrolysis increased from $1.0 \pm 0.1$ nmol·min$^{-1}$·mg$^{-1}$, in the absence of GTP, to $134 \pm 6$ nmol·min$^{-1}$·mg$^{-1}$, in the presence of 20 mM GTP, showing a ~130-fold enhancement (Fig. 2D), although the $K_m$ values were not appreciably different (Table S4). Systems that demonstrate altered catalytic rates ($V_{max}$ or $k_{cat}$) are described as ‘V-type’ systems [16]. Activation of pNPP hydrolysis by GTP is ‘V-type’ because the activator increases the $V_{max}$ without altering the $K_m$. The intersection patterns in the plots of $1/v$ versus $1/[pNPP]$ at different fixed [GTP] and $1/v$ versus $1/[GTP]$ at different fixed [pNPP] (Fig. S2C,D) are indicative of random binding of GTP and pNPP to the enzyme and also confirm that the activation of pNPP hydrolysis brought about by GTP is nonessential ‘V-type’, without significant variation in $K_m$ values.
Effect of GMP, GDP, IMP and ITP on pNPP hydrolysis

GMP activation of pNPP hydrolysis

GMP activates pNPP hydrolysis by ~15-fold and the initial velocity plot becomes sigmoidal in the presence of this nucleotide (Fig. 3A and inset). The $K_m$ for pNPP in the absence of GMP is $4.5 \pm 0.7$ mM and in the presence of 15 mM GMP, the $S_{0.5}$ becomes $7.0 \pm 0.4$ mM ($S_{0.5}$ is defined as the concentration of substrate required for half-maximal activity for an allosteric enzyme). The marginal increase in the $K_m$ /

Fig. 2. Activation of GMP and pNPP hydrolysis by GTP. (A) Initial velocity versus [GMP] plots at different fixed GTP concentrations. (Inset) The double-reciprocal plot shows the disappearance of the nonlinear nature of the curves with increasing GTP concentrations. The velocity on the y-axis is normalized to 1. Curves were fitted to the Hill equation. SA stands for the specific activity of the enzyme. (B) Activation of GMP hydrolysis by GTP examined by ion-pair RP-HPLC. The reactions were carried out in Tris/HCl, pH 7.4, 30 mM MgCl$_2$ and 1.5 mM GMP. 1 mM of GTP was used in the reaction where the effect of the activator was to be assessed. The dotted line represents the hydrolysis of GMP in the absence of GTP and the solid line represents the hydrolysis of GMP in the presence of 1 mM GTP. For the unactivated reaction, the area under the peak for GMP and guanosine was 1053 ± 62 and 129 ± 14, respectively. For the activated reaction, the area under the peak for GMP and guanosine was 342 ± 48 and 813 ± 220, respectively. Values are an average of three measurements. The peak areas were integrated using the AKTA™ Basic HPLC software UNICORN, v. 5.11(GE Healthcare Bio-Sciences Corp., NJ, USA). (C) Activation of pNPP hydrolysis by GTP. Time scans of pNPP hydrolysis in the absence and presence of GTP are represented by dotted and solid lines, respectively. The y-axis is broken for ease of visualization. The inset shows pNPP titration in the absence (solid line) and presence (dotted line) of ATP. (D) pNPP titration in the absence and presence of GTP. The y-axis is broken for ease of visualization. The data points were fit using the linear and nonlinear curve fitting algorithms of GRAPHPAD PRISM software (GraphPad Software, Inc.), v. 4.0.
$S_{0.5}$ for pNPP might be because of competition at the active site.

**GMP and GDP bind to the GTP-binding site**

GMP was found to bring about a twofold reduction in the activation of pNPP hydrolysis by GTP, as evident from comparison of time course measurements of substrate hydrolysis in the presence of GTP alone, GMP alone and combined equimolar quantities of GMP and GTP (Fig. S3A). To understand the mechanism of reduction in GTP activation and the site to which GMP binds to bring about activation, a competition assay was carried out, wherein [GTP] was varied at several fixed concentrations of GMP and saturating [pNPP], whose hydrolysis was monitored at 405 nm. The plot showed lines intersecting on the $1/v$ axis (Fig. 3B) indicative of competitive displacement of GTP by GMP at the activator-binding site. The reverse plot, wherein GMP is titrated at several fixed concentrations of GTP with the hydrolysis of pNPP monitored at 405 nm, shows a concentration-dependent decrease in pNPP hydrolysis with increasing GMP (Fig. S3B), attesting to the observation that GMP competitively reduces the activation brought about by GTP. GDP was also found to compete for binding to the GTP-binding site and bring about a concentration-dependent reduction in the activation of pNPP hydrolysis by GTP (Fig. S3C). Guanosine at a concentration of 5 mM was also found to compete weakly for the GTP-binding site (Fig. S3D); guanine alone could not be tested because of its poor solubility. These results suggest that at least one phosphate is necessary for effective activation, with the potency of activation being highest for GTP, followed by GDP and GMP.

**IMP and ITP bind to the GTP-binding site**

Although IMP and ITP do not activate pNPP hydrolysis, they reduce the activation of pNPP hydrolysis brought about by GTP. The competitive intersection pattern of the lines in Fig. 3C and Fig. S3E indicate that IMP and ITP bind to the GTP-binding site. Taken together, these observations indicate that the oxo-group at C6 is essential for binding to the activator site, whereas the amino group at C2 is essential for bringing about activation. By contrast, ATP does not affect the activation of pNPP hydrolysis brought about by GTP (Fig. S3F).
Crystallographic studies

The structure of L. pneumophila was solved in complex with PO$_4^-$ (PDB ID 4G63) and GMP (PDB ID 4OHF) at 2.7 and 2.5 Å, respectively. The PO$_4^-$-complexed structure at 2.7 Å resolution contains two phosphate ions, both present at sites on the protein that do not have known functional significance. The GMP-complexed structure at 2.5 Å resolution has one PO$_4^-$ at a location similar to one of the phosphates in the PO$_4^-$-complexed structure; the second PO$_4^-$ is present in the active site. The structure of LpcN-II in complex with GMP contains four molecules in the asymmetric unit of space group C2 and the PO$_4^-$-complexed structure contains one molecule in the asymmetric unit of space group I4$_1$22, with the tetramer being generated from crystallographic symmetry.

Tertiary and quaternary structures of LpcN-II

LpcN-II exhibits a two-domain organization with a core domain and a cap domain. The core (D2-R30, K183-E325, D424-I459) is an α/β-domain containing an eight-stranded parallel β sheet surrounded by seven α helices, characteristic of the α/β Rossmann fold (Fig. 4A). The cap domain (Y31-K182, N403-V423) has a mixed α/β organization with eight α helices and seven β strands clustering separately (PDBsum). There is a helical extension of ~76 residues (from E326 to Y402) characteristic of cN-II nucleotidases. There are two distinct interfaces constituting the LpcN-II tetramer, the dimeric interface and the tetrameric interface (Fig. 4B). The subunits are related by 180° rotations about the axis through the dimeric and tetrameric interfaces. The interface across nonadjacent subunits makes 19 contacts at the 4 Å cut-off involving five residues (K77, R110, N120, Q154 and Q158).

Active site of LpcN-II

The GMP-complexed LpcN-II structure has a phosphate ion coordinated to the Mg$^{2+}$ present in the active site, located between the core and the cap domains (Fig. 5A). Electron density for Mg$^{2+}$ is absent in the A subunit, whereas electron density for phosphate is seen in all four subunits, even at 6σ. The four catalytic motifs, motif I [DXDX (T/V)], motif II [(T/S)], motif III [(K/R)] and motif IV (DX$_{0-4}$D), characteristic of HAD superfamily enzymes [17], are conserved in LpcN-II. Contacts between phosphate and active site residues Asp23 and Asp25 (motif I), Thr209 (motif II), Lys247 (motif III) and Asp303 (motif IV) are largely similar across subunits.

Effector-binding site

The effector-binding site, located at the dimer interfaces, could be seen in the GMP-bound structure (Fig. 5B), in which there is sufficient electron density for only the GMP moiety (Fig. 5C) of GMP-PNP despite soaking the crystals in fresh GMP-PNP and MgCl$_2$ prior to data collection. Moreover, although the electron densities for the α-phosphate and the ribose of GMP-PNP were poor, the guanine group could be clearly visualized. Despite the presence of

![Fig. 4. PO$_4^-$-complexed monomeric (A) and tetrameric (B) LpcN-II structures. (A) The respective domains have been marked as CAP, CORE-ROSSMANN FOLD and HELICAL EXTENSION. (B) DI represents dimer interface and TI, the-tetramer interface. All structure figures were generated with PYMOL (DeLano Scientific LLC), Portland, OR, USA.](image-url)
Mg$^{2+}$ in the crystallization buffer, the absence of Mg at the effector-binding site might have contributed to the disorder of the beta and gamma phosphates of GMP-PNP. In the structure of SRP GTPase complexed to GMP-PNP, it has been suggested that an increase in the temperature factor for $\beta/\gamma$ phosphates is due to the absence of Mg$^{2+}$ ions [18]. Further, in the ATP/IMP-complexed human cN-II structure, $\beta/\gamma$ phosphates that are well ordered are coordinated to Mg$^{2+}$ [14].

The effector site consists of residues Arg86, Tyr87 and Tyr421 from both subunits and Asp308 and Arg425 from only one subunit of the dimer (Fig. 5B). Tyr421 and Tyr87 stack above and below the purine ring of GMP. Arg86 from both subunits contacts O6 of GMP. The corresponding residue in the human enzyme is Ala114. Interactions of O6 with Arg86 may be the key determinant of the binding specificity of ITP and GTP over ATP. The N2 amino group of GMP is involved in forming a hydrogen bond with the backbone O of Arg86. This interaction would be absent in ITP because it lacks the C2 amino group. These interactions may be the reason why guanine nucleotides both bind and activate LpcN-II, whereas ATP, the human cN-II activator, does not. Most importantly, the site of GMP binding is ~25 Å away from the catalytic aspartate of the active site, reinforcing the observation from kinetics that the substrate also binds to a site distal from the active site to bring about activation.

---

**Fig. 5.** Active site and effector-binding site in LpcN-II. (A) Active site of GMP-complexed LpcN-II structure (blue) superposed with human BeF$_3$-complexed structure (green, PDB ID 2JCM). Shown also is motif IV in ribbon format and GMP (shown in CPK color) in the effector site of LpcN-II. BFSD5 represents BeF$_3$ covalently linked to D52 in the human structure. Dashed lines indicate hydrogen bonds and are shown only for LpcN-II, except for the water-mediated hydrogen bond from Asp356 to Mg$^{2+}$ (green sphere) from the human cN-II structure. The water molecule is shown as a red sphere. Mg$^{2+}$ from the LpcN-II structure is shown as a blue sphere. (B) Residues in the activator-binding site that make contact with GMP. GMP is colored blue for carbon atoms, and residues from the two monomers are colored green and magenta. Dashed lines indicate hydrogen bonds. (C) The electron density for GMP from omit 2Fo−Fc map seen at 1σ.
Validation of the effector-binding site by mutagenesis

Given the poor electron density for the ligand molecule in the GMP-complexed LpcN-II structure, and given that the mode of activator binding in the human and Legionella enzymes are different, it was important to validate the ligand-binding site using site-directed mutagenesis. Based on contact analysis, two residues, viz. Y421 and R86, were selected and mutated to their respective human counterparts, Ser and Ala, respectively. A double mutant Y421S/R86A was also generated. The mutants were purified to homogeneity and found to elute as tetramers on analytical size-exclusion chromatography, indicating that the introduction of mutation(s) at the interface had not perturbed their oligomeric status (Fig. S4A,B). Although the single and double mutants displayed the same level of basal activity as the wild-type for the substrate pNPP, activation of pNPP hydrolysis by GTP was compromised in the case of the single mutants (Y421S and R86A) and abolished in the case of the double mutant (Y421S/R86A; Fig. 6A,B). ATP was still unable to activate the mutant enzymes. Further, the double mutant displayed biphasic kinetics and nonlinear double reciprocal plots (indicative of negative cooperativity) for GMP hydrolysis in both the presence and absence of the heterotropic activator GTP (Fig. 6C and inset). Taken together, these kinetic features confirmed the activator-binding site and also supported the substrate activation model, wherein substrate binds to an alternate site on the enzyme and allosterically modulates its affinity for the active site. It should be noted that the initial velocity curves for IMP were also biphasic (Fig. 1C) given that its binding to the allosteric site (reduces the activation of pNPP hydrolysis by GTP, Fig. 3C) does not activate the enzyme.

Structure alteration upon activator binding and probable mode of activation

When the Cα trace (excluding residues 339–397 and 450–462, constituting the helical extension and the C-terminus of the protein, respectively) of the monomers of the PO₄-complexed and GMP-complexed structures from LpcN-II were superposed, an RMSD of 0.84 Å was obtained. Although the core and the cap domains of the two structures superposed well, the helical extension showed a rotation in the GMP-complexed structure vis-à-vis the PO₄-complexed structure. Moreover, this rotation of the helical extension was 13.4° and 4.5° for subunit A (green in Fig. 7A) and B (magenta in Fig. 7A) of the GMP-complexed dimer, respectively, with respect to that of PO₄-complexed structure (yellow in Fig. 7A). This asymmetry in rotation is a reflection of the asymmetry of the ligand bound at the symmetric dimeric interface. Further structural alterations became obvious on comparing the dimer organization of the PO₄-complexed and GMP-complexed LpcN-IIs (Fig. 7B), wherein significant differences in terms of the buried surface area and number of salt bridges at subunit interfaces were observed. The PO₄-complexed structure buries 4696 Å² at the dimer interface and contains six salt bridges, whereas the equivalent buried surface area at the dimer interface of the GMP-complexed structure is 5985 Å² and contains twelve salt bridges [19]. This tightly associated reorganization of the LpcN-II oligomer brought about by GMP binding to the effector site could serve as a structural basis for allosteric activation.

Examination of the structure shows the presence of connectivity between the effector and active sites through segment Arg70-Tyr87 that forms part of a β-hairpin structure with the guanidinium group of Arg70 making contact with the catalytic Asp303 and His304 of motif IV. This entire segment is part of the cap domain and bridges the active site and the activator site (Fig. 5A). When examined across cN-IIs from different species, this 17-residue peptide segment shows a significant degree of conservation (Fig. 5B), suggesting its possible role in modulating allosterism in other cN-IIs also. Further, residues 303–308 that are part of motif IV, form connectivity between the effector-binding site and the active site, which is established by an Asp308-GMP (PO₄ group) contact at one end of motif IV in the effector site and Asp303-Mg²⁺ contact at the active site (Fig. 5A). This connectivity is seen only in one subunit of the dimer since a single effector molecule is present at the dimeric interface.

Comparison of human cN-II structure with LpcN-II

Phylogenetic analysis of cN-II sequences from the different kingdoms of life shows that LpcN-II is distantly related to mammalian cN-IIs (Fig. S6A). Prokaryotic cN-IIs lack the C-terminal acidic stretch (made of polyaspartates or polyglutamates) that is found in cN-IIs from the animal kingdom (Fig. S6B). In mammalian cN-IIs, this acidic stretch has been implicated in mediating enzyme aggregation and activation [12]. Human and L. pneumophila cN-IIs share 32% sequence identity and superposition of the PO₄-complexed LpcN-II and human cN-II monomeric structures shows an RMSD of 1.3 Å. However,
The superposition of the two dimers leads to an increased RMSD of 1.9 Å, indicating significant differences in the dimeric organization between human and LpcN-II structures (Fig. 7C). Two key differences between the structures are the presence of ~30 additional residues at the N-terminus of the human protein that do not have a counterpart in the *Legionella* enzyme and the absence of the stretch from N174 to F191 (human numbering) in the *Legionella* enzyme. In the human structure only, this segment makes extensive contacts at the tetramer interface. In addition, the LpcN-II structure has contacts across nonadjacent subunits that are absent in the human structure. Further, a substantial part (~18 residues) of the helical extension is not modeled in the human cN-II structure.

The active site residues seen in LpcN-II are conserved in human cN-II and other haloacid dehalogenases. In the BeF₃ complexed human cN-II structure, the side chain of Asp52 is covalently bonded to BeF₃, a phosphate mimic. The side chain of the corresponding residue, Asp23 in LpcN-II has a different orientation in the active site of the GMP-complexed structure.
A notable exception is the position of Asp308 in LpcN-II, which is significantly away from the active site, whereas in the various nucleotide and BeF₃-complexed human cN-II structures, the corresponding residue Asp356 contacts Mg²⁺ at the active site through a water-mediated hydrogen bond.

Comparison of the effector conformation and the binding site shows that LpcN-II has novel features that are distinct from human cN-II. LpcN-II has one ligand at each dimer interface leading to a stoichiometry of two protein subunits to one nucleotide. This is in stark contrast to ATP-complexed human cN-II in which two ligand molecules bridged by a single Mg²⁺ are seen at the dimer interface. The conformation of GMP is syn in LpcN-II, whereas the ATP is anti in human cN-II. A syn conformation of the guanine nucleotide is seen in the structure of GDP-fucose complexed to MUR1 GDP-mannose 4,6-dehydratase from Arabidopsis thaliana [20].

The residues contacting adenosine [13], ATP, AP₄A and 2,3-bisphosphoglyceric acid in the various complexed human cN-II structures [14] are not conserved.
in LpcN-II. Comparison of the residues contacting the ligand in the GMP-complexed LpcN-II structure with their human counterpart shows that only Tyr87 of LpcN-II is conserved as Tyr115 in the human enzyme, whereas Tyr421 and Arg86 of LpcN-II correspond to Ser 452 and Ala114, respectively, in the human enzyme.

Although human cN-II does not show a change in subunit organization upon effector binding (Fig. 7D), the segment corresponding to motif IV referred to as helix A undergoes a disorder to order transition upon ligand binding. The ordering of this helix results in repositioning of Asp356 such that it contacts the active site Mg\(^{2+}\) through a water bridge. Although this ordering is suggested to be induced only upon activator binding, the BeF\(_3\)-complexed structure (PDB ID 2JCM) lacking the activator also has the helix ordered and Asp356 repositioned. A distinct difference from the human activator-bound structure is the absence of Asp308 movement to the active site upon effector binding in LpcN-II. The conformation of motif IV in LpcN-II remains undisturbed upon effector binding. With the observation of these differences between human and LpcN-II, the role of Asp308 in activation needs examination by mutagenesis. Finally, it should be noted that while LpcN-II is full-length and active, the human cN-II clone studied has a truncation at the C-terminus resulting in almost complete loss of activity [12].

**Discussion**

Nucleotides are components of several vital cellular processes, and the enzymes involved in nucleotide metabolism are tightly regulated to ensure homeostasis. The cN-II class of 5'-nucleotidases from mammalian sources plays several roles essential in oxypurine cycling, nucleotide monophosphate degradation, and maintenance of NMP pools through their phosphotransferase reaction [2] and, hence, are tightly regulated allosterically. The current study throws light on the presence of Asp356 such that it contacts the active site Mg\(^{2+}\) through a water bridge. Although this ordering is suggested to be induced only upon activator binding, the BeF\(_3\)-complexed structure (PDB ID 2JCM) lacking the activator also has the helix ordered and Asp356 repositioned. A distinct difference from the human activator-bound structure is the absence of Asp308 movement to the active site upon effector binding in LpcN-II. The conformation of motif IV in LpcN-II remains undisturbed upon effector binding. With the observation of these differences between human and LpcN-II, the role of Asp308 in activation needs examination by mutagenesis. Finally, it should be noted that while LpcN-II is full-length and active, the human cN-II clone studied has a truncation at the C-terminus resulting in almost complete loss of activity [12].

Brain IMP-GMP-specific 5'-nucleotidase that is allosterically activated by Ap\(_4\)A. This activator displays a mixed-type mechanism with IMP as the substrate, with an increase in \(V_{\text{max}}\) and a decrease in \(K_m\), and an exclusive K-type mechanism on the substrates GMP, AMP and XMP [7–11,21,22]. Unexpectedly, the K-type activation in LpcN-II has not resulted in a large decrease in \(K_m\) value for GMP, because of GMP partitioning to both the activator and active site. Hence, a true reduction in the \(K_m\) value in the presence of GTP could not be estimated and the experimentally derived \(K_m\) is an ‘apparent’ value.

Activator binding at the dimeric interface brings about structural alterations, as evident from our crystallographic studies. These alterations were also evident in solution studies of LpcN-II, wherein partial trypsin proteolysis and CD spectroscopy were used as probes on the complexed and apo enzymes (data not shown). However, ligand binding did not confer any thermodynamic stability to the protein, as seen in urea and temperature denaturation studies (data not shown). Feedback inhibition by a downstream metabolite of an upstream anabolic enzyme to control the flux through a pathway is well documented in the literature [23], whereas feedback activation, wherein a downstream metabolite activates an upstream catalytic enzyme, is sparsely mentioned. In the case of LpcN-II, we present a case of feedback activation by GTP to deplete a precursor (GMP) and keep its level in control.

The promiscuous nature of the activator-binding site, whereby it can accommodate all guanine nucleotides, raises further interesting aspects. By far the most interesting of these interactions is that by the substrate GMP activating its own hydrolysis. Based upon observations that GMP activates LpcN-II’s pNPP hydrolysis and competitively reduces activation of pNPP hydrolysis by GTP, we surmise that substrate GMP binds to the allosteric GTP-binding site. Further, we propose that the sigmoidal nature of initial velocity versus [GMP] plots arises from GMP partitioning to both active and allosteric sites. Further, the crystallographic data, which show GMP density at the interface, provide unequivocal structural evidence for GMP-mediated activation. The high \(S_{0.5}\) values obtained for substrate GMP and dGMP might be a reflection on the fact that the substrate is partitioning between the allosteric activator-binding site and the active site. Substrate activity is a very rare phenomenon with only a few examples of enzymes being activated by substrates binding to a site distal from the active site [24,25]. The double mutant Y421S/R86A, wherein activation of pNPP hydrolysis by GTP is
completely abolished, also shows the abolishment of activation of pNPP hydrolysis by GMP (data not shown), validating that both GMP and GTP bind to the same allosteric activator site. Substrate activation by GMP of its own hydrolysis in LpcN-II, a catabolic enzyme, can be understood as a mechanism akin to inhibition of an anabolic enzyme by the product of its reaction.

The IMP titration curves for the wild-type LpcN-II display biphasic kinetics indicative of negative cooperativity, whereby substrate binding to one active site reduces the affinity of the substrate for the adjacent active site. This shows that substrate binding to the activator-binding site and subsequent activation are mandatory for the initial velocity versus (S) plots to show saturation. It should be recalled that although IMP binds to the activator-binding site (Fig. 3C), it does not activate the pNPP hydrolysis activity of LpcN-II. Further, upon abolishing the activator-binding site in the double mutant Y421S/R86A, the initial velocity versus (GMP) curve also showed biphasic kinetics. All of the above results lead us to speculate that the biphasic behavior seen in the initial velocity plots for IMP is switched to a sigmoidal response curve in GMP plots because the latter substrate is also capable of bringing about allosteric activation. This behavior is interesting from the perspective that the catabolic role of the enzyme might be directed towards depleting GMP/IMP pools depending on the levels of guanine nucleotides.

In conclusion, we have shown that LpcN-II is regulated at multiple levels. Biochemical and structural evidence suggests that the prokaryotic enzyme is modulated differently from its mammalian counterpart. Moreover, we postulate that the structural demonstration of subunit reorganization upon activator binding is the probable mechanism for homotropic and heterotropic activation by substrate and the activator, respectively.

**Experimental procedures**

**Reagents**

Unless mentioned otherwise, all reagents and chemicals were of high quality and were procured from Sigma-Aldrich Co. (St. Louis, MO, USA) or Merck India (Mumbai, India). The purity of GTP, GDP and GMP were confirmed by HPLC. Gel-filtration matrices were from Amersham Biosciences (Little Chalfont, UK). Media components were from Himedia (Mumbai, India). Macrosep centrifugal devices were from Pall Co. (MA, USA). Crystallization cocktail buffers were from Hampton Research (CA, USA).

**Bioinformatics analysis**

The sequence of LpcN-II was obtained from NCBI. The nonredundant database at NCBI was used to search for homologs of LpcN-II using the algorithm BLASTP. Distant homology searches were carried out using PSI-BLAST [26]. T-COFFEE [27] was used to generate multiple sequence alignment profiles. Phylogenetic and molecular evolutionary analyses were carried out using MEGA, v. 3.1 [28]. Molecular visualization and structure analysis were done using various tools like SPDBV [29], Pymol (pymol.sourceforge.net) and the CCP4 suite of programs [30].

**Cloning, expression and purification of wild-type LpcN-II**

The gene expressing the protein was cloned in a pET21 derivative, expressed by transforming in *Escherichia coli* BL21 (DE3) pMgK cells and purified by immobilized nickel-affinity chromatography. The detailed protocol is given in supplemental methods.

The oligomeric status of the protein was probed by size exclusion chromatography on a pre-calibrated analytical Superdex-200 column (see Doc. S1 for a detailed protocol).

**Construction of Y421S, R86A and Y421S/R86A LpcN-II mutants**

Site-directed mutants of the wild-type LpcN-II were generated by the quick change PCR method using a single mutagenic oligonucleotide primer [31]. Primers 5'-AATATTTTAAAACGTAGCCATATGGTTGCCATTAGATTG-3' and 5'-GAGAGCTACTTCGCTAGCCAAGTTGATAGATTC-3' were used for the generation of R86A and Y421S mutants, respectively, using wild-type gene as template. The double mutant Y421S/R86A was generated using Y421S mutant LpcN-II as template. The PCR product was digested with *Dpn*I and transformed into *E. coli* XL1 Blue strain. The site of mutation was confirmed by restriction analysis for the introduced restriction site and by sequencing. The plasmid was isolated and transformed into *E. coli* XL1 Blue strain. The site of mutation was confirmed by restriction analysis for the introduced restriction site and by sequencing. The plasmid was isolated and transformed into *E. coli* Rosetta (DE3) pLysS for expression studies with ampicillin and chloramphenicol as selection markers. Conditions for expression and purification of all three mutant enzymes were kept same as that for the wild-type enzyme.

**Activity assays**

Phosphate ester hydrolysis of various nucleotide monophosphates by LpcN-II was monitored using Chen’s assay [32] with slight modifications. pNPP hydrolysis assays were carried out in 50 mM Tris/HCl, pH 8.0 in a final reaction
volume of 250 µL using a double-beam Hitachi UV 2010 (Hitachi High Technologies America, Inc., San Jose, CA, USA) spectrophotometer. The details of the assay are provided in Doc. S1.

Screening for activators of LpcN-II activity

Various activators were screened to assess their effect on the pNPP-hydrolyzing activity of LpcN-II. The detailed protocol and the metabolites tested are summarized in Doc. S1 and Table S2.

Determination of $K_D$ of (activator-Mg$^{2+}$) complexes of LpcN-II

The $K_D$ values for the GTP-Mg$^{2+}$-enzyme complex, dGTP-Mg$^{2+}$-enzyme complex and GDP-Mg$^{2+}$-enzyme complex were determined kinetically (under catalytic conditions), whereas that of the GTP-Mg$^{2+}$-enzyme complex alone was also determined under conditions of equilibrium with radiolabeled GTP. The details of the protocol are specified in Doc. S1.

Kinetics of GTP activation

Activation of GMP hydrolysis by GTP

Activation of GMP hydrolysis by GTP was monitored by ion-pair RP-HPLC [33] and Chen’s assay. The details of the protocol are specified in Doc. S1.

Activation of pNPP hydrolysis by GTP

Activation of pNPP hydrolysis by GTP was monitored by performing activation kinetics. The details of the protocol are specified in Doc. S1.

Crystallization and data collection

Summaries of the crystallization and data collection strategies for the PO$_4$-complexed and GMP-PNP-complexed LpcN-II are provided in Doc. S1 and Table S5. Data collection and model building statistics are as summarized in Table 2.

Phasing, model building and refinement

The diffraction images of both SO$_4$- and PO$_4$-complexed LpcN-II were processed with the HKL package [34] and the selenium sites of SO$_4$-complexed LpcN-II were located with the program snb [35]. SOLVE/RESOLVE [36] was used for phasing the reflections and automated model building, which correctly placed 15% of the residues with side chains. The majority of the model was built manually with the program XTALVIEW [37]. Structure refinement was performed with CNS [38]. The model of the SO$_4$-complexed structure (PDB entry: 2BDE) was subsequently used to determine the structure of PO$_4$-complex using the molecular replacement method with the program COMO [39]. The data processing and refinement statistics are summarized in Table 2.

The structure of SO$_4$-complexed LpcN-II was also used as the search model for the structure solution of GMP-complexed LpcN-II by molecular replacement with the program MOLREP [40]. Reflections in the resolution range 44.7–2.53 Å of this crystal form were used for the rotation and translation searches. The highest peak of the translation search had a correlation coefficient of 45.311% and an $R$-factor of 51.035%. The structure of the GMP-complexed cN-II was solved with four polypeptides per asymmetric unit. Refinement was initiated with the program CNS 1.3. The 2$F_o$−$F_c$ map calculated after initial positional refinement showed a reasonable fit for the majority of the main chain atoms except for those that belonged to the region comprising residues 360–400. Subsequent rounds of model building and refinement were carried out using the programs XTALVIEW [37] and CNS in which specification of NCS restraints helped reduce both the $R$-factor and $R_{free}$ of the model considerably. Inspection of the difference ($F_o$−$F_c$) map showed positive electron density for the GMP moiety of GMP-PNP. Potential sites for solvent molecules were identified both manually and using the automatic water-picking algorithm of CNS 1.3. The structure was refined to a final $R/R_{free}$ of 0.23/0.27 to a resolution of 2.53 Å. Refinement statistics are as specified in Table 2.

<table>
<thead>
<tr>
<th>Table 2. Data collection and refinement parameters for the PO$_4$-complexed and GMP-complexed crystal forms of LpcN-II.</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO$_4$-complexed LpcN-II</td>
</tr>
<tr>
<td>Resolution</td>
</tr>
<tr>
<td>No. of reflections</td>
</tr>
<tr>
<td>No. of reflections for $R_{free}$</td>
</tr>
<tr>
<td>$R_{value}$</td>
</tr>
<tr>
<td>$R_{free}$</td>
</tr>
<tr>
<td>RMS deviation – bond length</td>
</tr>
<tr>
<td>RMS deviation – bond angle</td>
</tr>
<tr>
<td>Mean B-value (overall)</td>
</tr>
<tr>
<td>B-value from Wilson plot</td>
</tr>
<tr>
<td>% Residues (most favorable)</td>
</tr>
<tr>
<td>% Residues (additionally allowed)</td>
</tr>
<tr>
<td>% Residues (generously allowed)</td>
</tr>
<tr>
<td>% Residues (disallowed)</td>
</tr>
<tr>
<td>PDB ID</td>
</tr>
</tbody>
</table>

1626
Acknowledgements

We would like to thank the X-ray crystallographic facility at the Molecular Biophysics Unit, Indian Institute of Science, Bangalore for providing machine time to facilitate the collection of data. We would also like to thank Dr Kiran Kulkarni for assistance with structure solution. We thank Angela Lauricella and George DeTitta for setting up initial crystal screenings; Randy Abramowitz and John Schwanof for setting up the X4A beamline. Research at the NESG was supported by the Protein Structure Initiative of the National Institutes of Health (U54 GM074958 and U54 GM094597). The work was supported by funding from Department of Biotechnology and Department of Science and Technology, New Delhi, India. BS was supported by Council for Scientific and Industrial Research (CSIR) senior research fellowship, CS was supported by DBT-Postdoctoral fellowship, AS was supported by CSIR junior research fellowship. BS and FF have contributed equally to the work.

References


Supporting information

Additional supporting information may be found in the online version of this article at the publisher's website:

Fig. S1. Purification and characterization of LpcN-II.
Fig. S2. GTP-binding and activation of LpcN-II.
Fig. S3. Modulation of GTP activation by various ligands.
Fig. S4. Purification and characterization of LpcN-II mutants.
Fig. S5. Active site-allosteric site connectivity.
Fig. S6. Phylogenic tree and multiple sequence alignment of cN-IIIs from different organisms.
Table S1. Ligand screen to determine the substrate and cofactor for LpcN-II.
Table S2. Summary of the kinetic parameters of LpcN-II and cN-IIIs from various organisms.
Table S3. Screening for activators of LpcN-II activity.
Table S4. Kinetic parameters of the LpcN-II enzyme for the substrates, pNPP and GMP in the presence and absence of activator GTP.
Table S5. Summary of conditions under which the GMP-PNP-liganded LpcN-II was crystallized.